AR007060A1 - Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios - Google Patents

Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios

Info

Publication number
AR007060A1
AR007060A1 ARP970101926A ARP970101926A AR007060A1 AR 007060 A1 AR007060 A1 AR 007060A1 AR P970101926 A ARP970101926 A AR P970101926A AR P970101926 A ARP970101926 A AR P970101926A AR 007060 A1 AR007060 A1 AR 007060A1
Authority
AR
Argentina
Prior art keywords
alkyl
inhibitors
aryl
alkenyl
alkoxy
Prior art date
Application number
ARP970101926A
Other languages
English (en)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR007060A1 publication Critical patent/AR007060A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Inhibidores de la formación de CD23 humana soluble de la fórmula (I) en la que : R es hidroxi, hidrógeno, alquilo, alquenilo, alquinilo o arilo; R1 esarilmetilo o heterociclilmetilo; R2 es alquilo, alquenilo, arilo cicloalquilo o cicloalquenilo; yR 3 es hidrógeno, alquilo, alquenilo, alquinilo o arilo con lacondición de que: si R1 es fenilmetilo o naftilmetilo, en que el grupo fenilo o naftilo está sin sustituir o sustituido hasta con cinco sustituyentesseleccionados del grupo que consisteen halógeno, alquilo (C1-6) aril-alquilo (C1-6), alcoxi (C1-6)m alcoxi (C1-6)-alquilo (C1-6), halo-alquilo (C1-6),hidroxi, nitro, amino, mono- y di-N-alquil (C1-6)-amino, acilamino, aciloxi carboxi, sales de carboxi, ésteres de carboxi,carbamoíl o, mono y di-N-alquil(C1-6)-carbamoílo, alcoxi (C1-6)-carbonilo, ariloxi-carbonilo, ureído, guanidino, sulfonilamino, aminosulfonilo, alquil(C1-6)-tio, alquil(C1-6)-sulfinilo, alquilo (C1-6)-sulfonilo, heterociclilo,heterociclilalquilo (C1- 6), y una cadena alquileno (C3-5) que enlaza a dos átomos de carbono de anillosadyacentes para formar un anillo carbocíclico; entonces R es hidróxi; son útiles en el tratamiento de trastornos mediados por s-CD23. Sedescribe ademásel uso de los mismos, una compocisión farmacéutica que los contiene, un método para la preparación de dichos inhibidores, un compuesto de fórmula (II) y uncompuesto de fórmula (IV).
ARP970101926A 1996-05-10 1997-05-08 Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios AR007060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9609794.4A GB9609794D0 (en) 1996-05-10 1996-05-10 Novel compounds

Publications (1)

Publication Number Publication Date
AR007060A1 true AR007060A1 (es) 1999-10-13

Family

ID=10793494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101926A AR007060A1 (es) 1996-05-10 1997-05-08 Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios

Country Status (21)

Country Link
US (1) US6235753B1 (es)
EP (1) EP0918747B1 (es)
JP (1) JP2000510473A (es)
KR (1) KR20000010892A (es)
AR (1) AR007060A1 (es)
AT (1) ATE246673T1 (es)
AU (1) AU2897397A (es)
BR (1) BR9709450A (es)
CA (1) CA2253590A1 (es)
CO (1) CO4990945A1 (es)
CZ (1) CZ363198A3 (es)
DE (1) DE69723984T2 (es)
ES (1) ES2205218T3 (es)
GB (1) GB9609794D0 (es)
IL (1) IL126860A0 (es)
NO (1) NO985214L (es)
NZ (1) NZ332628A (es)
PL (1) PL329855A1 (es)
TR (1) TR199802271T2 (es)
WO (1) WO1997043249A1 (es)
ZA (1) ZA973964B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020082200A1 (en) * 1994-07-13 2002-06-27 Smithkline Beecham P.1.C. Use of inhibitors of human S-CD23
US6548084B2 (en) 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
CA2308361A1 (en) 1997-11-12 1999-05-20 Andrew Douglas Baxter Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
GB9813451D0 (en) * 1998-06-22 1998-08-19 Smithkline Beecham Plc Novel compounds
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
WO2001038322A1 (en) 1999-11-23 2001-05-31 Methylgene, Inc. Inhibitors of histone deacetylase
GB9930754D0 (en) * 1999-12-29 2000-02-16 Smithkline Beecham Plc Novel compounds
JP4790594B2 (ja) * 2003-02-25 2011-10-12 トポターゲット ユーケー リミテッド Ｈｄａｃインヒビターとしての、二環式ヘテロアリール基を含むヒドロキサム酸化合物
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EP2594557B1 (en) * 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
EP2860195A1 (en) 2009-12-01 2015-04-15 Boston Medical Center Corporation Treatment of IgE-mediated disease
EA026989B1 (ru) 2013-02-14 2017-06-30 Новартис Аг Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
TW201625569A (zh) * 2014-11-19 2016-07-16 艾克泰聯製藥有限公司 抗菌性苯并噻唑衍生物
AU2019352741A1 (en) 2018-10-04 2021-05-06 Assistance Publique-Hôpitaux De Paris (Aphp) EGFR inhibitors for treating keratodermas

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
DK0822186T3 (da) * 1994-01-20 2000-06-26 British Biotech Pharm L-tert-leucin-2-pyridylamid
GB9414157D0 (en) * 1994-07-13 1994-08-31 Smithkline Beecham Plc Medical use
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
DE19506492C2 (de) 1995-02-24 2003-05-08 Focke & Co Einrichtung zum Speichern von Zigaretten oder dergleichen
US5570079A (en) 1995-04-24 1996-10-29 Dockery; Devan Home security system for detecting an intrusion into a monitored area by an infrared detector

Also Published As

Publication number Publication date
ZA973964B (en) 1998-11-09
CO4990945A1 (es) 2000-12-26
TR199802271T2 (xx) 2000-08-21
US6235753B1 (en) 2001-05-22
IL126860A0 (en) 1999-09-22
ES2205218T3 (es) 2004-05-01
CA2253590A1 (en) 1997-11-20
JP2000510473A (ja) 2000-08-15
WO1997043249A1 (en) 1997-11-20
GB9609794D0 (en) 1996-07-17
NZ332628A (en) 2000-06-23
DE69723984D1 (de) 2003-09-11
NO985214L (no) 1998-12-01
BR9709450A (pt) 1999-08-10
ATE246673T1 (de) 2003-08-15
DE69723984T2 (de) 2004-06-09
PL329855A1 (en) 1999-04-12
KR20000010892A (ko) 2000-02-25
CZ363198A3 (cs) 1999-06-16
AU2897397A (en) 1997-12-05
EP0918747B1 (en) 2003-08-06
NO985214D0 (no) 1998-11-09
EP0918747A1 (en) 1999-06-02

Similar Documents

Publication Publication Date Title
AR007060A1 (es) Inhibidores de la formacion de la cd23 humana soluble, el uso de los mismos una composicion farmaceutica que los comprende, un metodo para preparar dichosinhibidores y compuestos intermediarios
MX9305379A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene.
AR016762A1 (es) Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
RU94040390A (ru) Производные виниленазаиндола, способ их получения, фармацевтическая композиция
PA8432901A1 (es) Compuestos de piridilpirrol
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
CO4810373A1 (es) Compuestos azapoliciclicos condensados con arilo
BR112019021853A2 (pt) Compostos de inibidor de vmat2 e composições dos mesmos
UY28101A1 (es) Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer
BRPI0512252A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto combinado, e, processo para a preparação de um composto
UY27700A1 (es) Compuestos oxo - azabiclícos.
AR018139A1 (es) Un compuesto n-[3-hidroxi-5[(1,4,5,6-tetrahidro-5-hidroxi-2-pirimidinil)amino]benzoil]glici-3-(3-halo-5-halo-2-hidroxifenil)-beta alanina, composicionfarmaceutica y uso del mismo en la fabricacion de un medicamento.
PT97500A (pt) Processo de producao de lipossomas e de preparados farmaceuticos contendo aqueles lipossomas
RU94036749A (ru) Замещенные 1-нафтилпиразол-3-карбоксамиды, способ их получения, содержащие их фармацевтические композиции и промежуточные соединения синтеза
AR016480A1 (es) Azoles hidrosolubles como antifungicos de amplio espectro, un proceso para su preparacion, un intermediario y una composicion farmaceutica que los comprende y el uso d elos mismos en la elaboracion de un medicamento
AR044175A1 (es) Compuestos de cefemo
KR900011724A (ko) 특정 피롤릴페닐-치환된 하이드록삼산 유도체
HUP9902119A2 (hu) Difenil-stilbén származékok, mint Cox-2 inhibitorok és ezeket tartalmazó gyógyszerkészítmények
UY27324A1 (es) Nuevas sales de napsilato i
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
RU2007121705A (ru) Антиинфекционные липопептиды

Legal Events

Date Code Title Description
FA Abandonment or withdrawal